Beijing Tiantan Biological Products Corp Ltd (600161) — Cash Flow-to-Debt Ratio
Beijing Tiantan Biological Products Corp Ltd (600161) has a Cash Flow-to-Debt Ratio of 0.20x as of September 2025, meaning its operating cash flow of CN¥318.80 Million could theoretically repay 0% of its total liabilities (CN¥1.60 Billion) in one year. See 600161 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Beijing Tiantan Biological Products Corp Ltd Cash Flow-to-Debt Ratio (1998–2024)
Historical debt coverage capacity for Beijing Tiantan Biological Products Corp Ltd across 27 annual periods. Also explore net asset momentum of Beijing Tiantan Biological Products Corp to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Beijing Tiantan Biological Products Corp Ltd (1998–2024)
Year-by-year debt coverage analysis for Beijing Tiantan Biological Products Corp Ltd. For market capitalisation and broader financial context, see market cap of Beijing Tiantan Biological Products Corp.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.61x | CN¥819.78 Million | CN¥1.34 Billion | ▼ -63.3% |
| 2023 | 1.67x | CN¥2.39 Billion | CN¥1.43 Billion | ▲ +134.9% |
| 2022 | 0.71x | CN¥1.13 Billion | CN¥1.58 Billion | ▼ -5.0% |
| 2021 | 0.75x | CN¥980.35 Million | CN¥1.31 Billion | ▲ +60.9% |
| 2020 | 0.46x | CN¥702.11 Million | CN¥1.51 Billion | ▼ -17.7% |
| 2019 | 0.57x | CN¥642.47 Million | CN¥1.14 Billion | ▼ -40.0% |
| 2018 | 0.94x | CN¥677.92 Million | CN¥720.19 Million | ▲ +107.5% |
| 2017 | 0.45x | CN¥218.39 Million | CN¥481.46 Million | ▲ +253.9% |
| 2016 | 0.13x | CN¥428.37 Million | CN¥3.34 Billion | ▼ -8.0% |
| 2015 | 0.14x | CN¥473.26 Million | CN¥3.40 Billion | ▲ +10.7% |
| 2014 | 0.13x | CN¥477.95 Million | CN¥3.80 Billion | ▼ -23.2% |
| 2013 | 0.16x | CN¥566.43 Million | CN¥3.46 Billion | ▲ +14.8% |
| 2012 | 0.14x | CN¥432.00 Million | CN¥3.03 Billion | ▼ -28.2% |
| 2011 | 0.20x | CN¥353.15 Million | CN¥1.78 Billion | ▲ +40.3% |
| 2010 | 0.14x | CN¥184.85 Million | CN¥1.31 Billion | ▼ -61.7% |
| 2009 | 0.37x | CN¥448.23 Million | CN¥1.21 Billion | ▼ -41.2% |
| 2008 | 0.63x | CN¥276.39 Million | CN¥439.35 Million | ▲ +51.3% |
| 2007 | 0.42x | CN¥153.55 Million | CN¥369.34 Million | ▼ -4.1% |
| 2006 | 0.43x | CN¥154.36 Million | CN¥356.20 Million | ▼ -40.9% |
| 2005 | 0.73x | CN¥131.69 Million | CN¥179.67 Million | ▼ -16.3% |
| 2004 | 0.88x | CN¥110.11 Million | CN¥125.70 Million | ▲ +121.7% |
| 2003 | 0.40x | CN¥62.93 Million | CN¥159.24 Million | ▲ +1.0% |
| 2002 | 0.39x | CN¥84.38 Million | CN¥215.73 Million | ▲ +46.1% |
| 2001 | 0.27x | CN¥46.49 Million | CN¥173.64 Million | ▼ -6.8% |
| 2000 | 0.29x | CN¥47.90 Million | CN¥166.77 Million | ▲ +7.8% |
| 1999 | 0.27x | CN¥42.58 Million | CN¥159.88 Million | ▲ +26.4% |
| 1998 | 0.21x | CN¥23.71 Million | CN¥112.54 Million | — |